Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis

Next Previous
Trial Profile

Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Atopic dermatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms TRuE AD2
  • Sponsors Incyte Corporation

Most Recent Events

  • 28 Feb 2025 According to an Incyte Corporation media release, ePoster featuring new data from this trial will be presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting, being held March 7-11, 2025, in Orlando.
  • 16 Oct 2024 According to an Incyte media release, Health Canada has granted a Notice of Compliance for OPZELURA cream 1.5%, a non-steroidal topical Janus Kinase (JAK) inhibitor, for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 12 years of age and older. This approval was based on TRuE-AD program.
  • 15 Feb 2024 Results of pooled analysis (N=1208) from TRuE-AD1 and TRuE-AD2 studies assessing efficacy and tolerability of ruxolitinib cream published in the Journal of Dermatological Treatment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top